---
title: "T14.SG (T14.SG) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/T14.SG/news.md"
symbol: "T14.SG"
name: "T14.SG"
parent: "https://longbridge.com/en/quote/T14.SG.md"
datetime: "2026-05-21T09:06:45.924Z"
locales:
  - [en](https://longbridge.com/en/quote/T14.SG/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/T14.SG/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/T14.SG/news.md)
---

# T14.SG (T14.SG) — Related News

### [DRTG's revenue has declined for three consecutive years, with last year's sales of the fast-acting rescue heart pill exceeding 2.1 billion yuan, and R&D investment of less than 200 million yuan](https://longbridge.com/en/news/281709747.md)
*2026-04-05T11:42:15.000Z*
> DRTG released its 2025 annual report, with total revenue of 4.917 billion yuan, a year-on-year decline of 32.7%; net pro

### [The controlling shareholder of DRTG's concerted action party plans to increase its holdings of the company's S shares by RMB 14.3 million to RMB 28.59 million](https://longbridge.com/en/news/274979306.md)
*2026-02-05T13:12:23.000Z*
> The controlling shareholder of DRTG, JinYao International Co., Ltd., plans to increase its holdings of the company's S s

### [The Brand Engineering Index closed at 2021.77 points last week](https://longbridge.com/en/news/265036607.md)
*2025-11-09T21:33:44.000Z*
> Last week, the market fluctuated upward, with the China Securities Xinhua National Brand Project Index closing at 2021.7

### [TJ DaRenTang: In the first three quarters, the net profit excluding non-recurring items exceeded 800 million yuan, with effective linkage between brand building and main product development](https://longbridge.com/en/news/263652427.md)
*2025-10-31T03:52:36.000Z*
> On the evening of October 30th, the traditional Chinese medicine "century-old brand" enterprise TJ DaRenTang disclosed i

### [Research Report Gold Mining | Guohai Securities: Initiates coverage on DRTG with a "Buy" rating, optimistic about the company's long-term growth potential](https://longbridge.com/en/news/253569564.md)
*2025-08-19T06:24:45.000Z*
> Guohai Securities initiates coverage on TJ DaRenTang with a "Buy" rating, believing the company's long-term growth poten

### [DRTG: In the first half of the year, the net profit attributable to the parent company was 1.928 billion yuan, showcasing the performance resilience of the "time-honored brand" led by the brand](https://longbridge.com/en/news/253167205.md)
*2025-08-15T08:10:09.000Z*
> On August 14th, after the market closed, the century-old traditional Chinese medicine company TJ DaRenTang disclosed its

### [TJ DaRenTang announced its semi-annual performance, with a net profit attributable to the parent company of 1.928 billion yuan, a year-on-year increase of 193.08%](https://longbridge.com/en/news/252991777.md)
*2025-08-14T08:31:03.000Z*
> TJ DaRenTang released its 2025 semi-annual report, with revenue of 2.651 billion yuan, a year-on-year decrease of 33.15%

### [Behind the surge in Tianjin Shike's mid-term profits: DRTG's revenue has declined consecutively and has faced regulatory penalties multiple times](https://longbridge.com/en/news/249219161.md)
*2025-07-19T00:55:09.000Z*
> DRTG expects a significant increase in net profit in the first half of 2025, mainly due to the after-tax net profit of 1

### [TJ DaRenTang: Tongmai Yangxin Pills strongly recommended in the Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disease](https://longbridge.com/en/news/249177371.md)
*2025-07-18T14:17:01.000Z*
> According to DRTG, the "Traditional Chinese Medicine Diagnosis and Treatment Guidelines for Coronary Microvascular Disea

### [TJ DaRenTang: Expected net profit in the first half of 2025 to increase by 180%-204% year-on-year](https://longbridge.com/en/news/248369818.md)
*2025-07-14T08:30:53.000Z*
> TJ DaRenTang announced that the company expects to achieve a net profit attributable to the owners of the parent company